重大事件
即時報告
8-K
2026-05-27
Tonix製藥提交8-K報告，附大量附件暗示重大臨床進展
AI 繁中摘要
Tonix Pharmaceuticals Holding Corp.（股票代碼：TNXP）於 2026 年 5 月 27 日向 SEC 提交了一份 8-K 現行報告（申報號：0001493152-26-025324）。📄
報告涵蓋三項主要事項：
- **Item 7.01：監管 FD 披露** — 公司依據公平披露規則發布非公開資訊。
- **Item 8.01：其他事件** — 涉及公司認為對股東重要的額外更新。
- **Item 9.01：財務報表及附件** — 隨附兩份關鍵附件（EX-99.01 及 EX-99.02）及多張圖形文件，可能包含詳細新聞稿或演示資料。
Tonix 總部位於新澤西州 Berkeley Heights，屬製藥行業（SIC 2834），目前正處於臨床階段，專注於傳染病、中樞神經系統疾病及疫苗研發。本次 8-K 未提供具體財務數字，但從附件數量（49 份文件）及大量圖形展示推測，公司可能發布了重要的臨床進展、合作協議或融資安排。💰
🔍 對投資者的潛在影響：8-K 中的 FD 披露通常會影響短期股價波動，尤其對於未有營收的生物科技公司而言，任何監管更新或臨床數據均可能引發較大反應。建議投資者仔細閱覽附件 EX-99.01 及 EX-99.02 以獲取完整資訊，並留意後續市場動向。
展開英文正文
EDGAR Filing Documents for 0001493152-26-025324 SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001493152-26-025324 Filing Date 2026-05-27 Accepted 2026-05-27 07:05:55 Documents 49 Period of Report 2026-05-27 Items Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K form8-k.htm iXBRL 8-K 42784 2 EX-99.01 ex99-01.htm EX-99.01 23504 3 EX-99.02 ex99-02.htm EX-99.02 30231 4 GRAPHIC ex99-01_001.jpg GRAPHIC 44167 5 GRAPHIC ex99-02_001.jpg GRAPHIC 353527 6 GRAPHIC ex99-02_002.jpg GRAPHIC 549698 7 GRAPHIC ex99-02_003.jpg GRAPHIC 187394 8 GRAPHIC ex99-02_004.jpg GRAPHIC 510795 9 GRAPHIC ex99-02_005.jpg GRAPHIC 551340 10 GRAPHIC ex99-02_006.jpg GRAPHIC 497603 11 GRAPHIC ex99-02_007.jpg GRAPHIC 520204 12 GRAPHIC ex99-02_008.jpg GRAPHIC 553059 13 GRAPHIC ex99-02_009.jpg GRAPHIC 495444 14 GRAPHIC ex99-02_010.jpg GRAPHIC 518840 15 GRAPHIC ex99-02_011.jpg GRAPHIC 516485 16 GRAPHIC ex99-02_012.jpg GRAPHIC 430302 17 GRAPHIC ex99-02_013.jpg GRAPHIC 440756 18 GRAPHIC ex99-02_014.jpg GRAPHIC 400370 19 GRAPHIC ex99-02_015.jpg GRAPHIC 456953 20 GRAPHIC ex99-02_016.jpg GRAPHIC 428000 21 GRAPHIC ex99-02_017.jpg GRAPHIC 416056 22 GRAPHIC ex99-02_018.jpg GRAPHIC 480340 23 GRAPHIC ex99-02_019.jpg GRAPHIC 508278 24 GRAPHIC ex99-02_020.jpg GRAPHIC 400024 25 GRAPHIC ex99-02_021.jpg GRAPHIC 524404 26 GRAPHIC ex99-02_022.jpg GRAPHIC 561646 27 GRAPHIC ex99-02_023.jpg GRAPHIC 566761 28 GRAPHIC ex99-02_024.jpg GRAPHIC 518563 29 GRAPHIC ex99-02_025.jpg GRAPHIC 568127 30 GRAPHIC ex99-02_026.jpg GRAPHIC 430549 31 GRAPHIC ex99-02_027.jpg GRAPHIC 421712 32 GRAPHIC ex99-02_028.jpg GRAPHIC 252263 33 GRAPHIC ex99-02_029.jpg GRAPHIC 436318 34 GRAPHIC ex99-02_030.jpg GRAPHIC 484761 35 GRAPHIC ex99-02_031.jpg GRAPHIC 471775 36 GRAPHIC ex99-02_032.jpg GRAPHIC 473067 37 GRAPHIC ex99-02_033.jpg GRAPHIC 439655 38 GRAPHIC ex99-02_034.jpg GRAPHIC 499582 39 GRAPHIC ex99-02_035.jpg GRAPHIC 364152 Complete submission text file 0001493152-26-025324.txt 22683475 Data Files Seq Description Document Type Size 40 XBRL SCHEMA FILE tnxp-20260527.xsd EX-101.SCH 3023 41 XBRL LABEL FILE tnxp-20260527_lab.xml EX-101.LAB 34239 42 XBRL PRESENTATION FILE tnxp-20260527_pre.xml EX-101.PRE 22364 54 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3205 Mailing Address 200 CONNELL DRIVE, SUITE 3100 BERKELEY HEIGHTS NJ 07922 Business Address 200 CONNELL DRIVE, SUITE 3100 BERKELEY HEIGHTS NJ 07922 212-980-9155 Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings) EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 261022147 SIC: 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)